Core Insights - IDEXX Laboratories, Inc. has launched the Catalyst® Cortisol Test, which provides real-time quantitative cortisol measurements to assist in diagnosing Addison's disease and managing Cushing's syndrome in dogs [1][4][5] Group 1: Product Launch and Features - The Catalyst Cortisol Test is the third expansion of the Catalyst platform within a year, enhancing diagnostic capabilities for veterinary practices [1][4] - This test allows for immediate diagnosis or ruling out of Addison's disease and Cushing's syndrome during patient visits, facilitating timely treatment [4][6] - The test will be available in the U.S. and Canada by the end of July 2025, with a global rollout expected to start in Q3 2025 [6] Group 2: Importance of the Test - Addison's disease is challenging to diagnose due to its nonspecific symptoms, making early detection crucial for effective treatment [3] - Cushing's syndrome, prevalent in older dogs, requires long-term management, and untreated cases can severely impact quality of life [3] - The Catalyst Cortisol Test improves long-term care for dogs with Cushing's syndrome by enabling tailored treatment adjustments [4] Group 3: Company Vision and Commitment - IDEXX emphasizes its commitment to advancing veterinary care through innovative solutions that enhance clinical insights and care delivery [5][7] - The test integrates with existing IDEXX systems, providing real-time interpretive guidance to streamline workflows for veterinary teams [8]

IDEXX Q1 2024 Earnings Highlights (NASDAQ: IDXX) IDEXX Q1 2025 Earnings Highlights (NASDAQ: IDXX) | Revenue | | | Operating | | | Diluted | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | Profit | | | Earnings Per Share | | | | | $998M | | | $317M | | | $2.96 | | | | | Reported growth: | +4% | 31.7% | of Revenue | | | | | | | | | | | | | | Reported growth: | | +5% | | | Organic growth: | +5% | YoY change in basis points: | | | | | | | | | CAG Diagnostics Recurring | | Reported | ...